AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 41 min read$NOVT

Glastra Matthijs sold $6K of NOVT

Glastra Matthijs (Chief Executive Officer) sold 38 shares of NOVANTA INC (NOVT) at $164.61 on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Glastra Matthijs
Published Jun 4, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NOVT
Neutral
high confidence
Mentioned
$NOVT
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NOVTNeutralLow
01

Why it matters

Insider selling can be interpreted as bearish, but 10b5-1 pre-arranged plans are designed to reduce timing-based inference; the disclosed sale is small and therefore less likely to move the stock materially.

02

Market read

A routine 10b5-1 insider sale disclosure for NOVT with limited incremental information for traders.

03

What to watch

The filing doesn’t reveal motivations beyond the plan; without additional transactions or changes in plan terms, signal quality is limited.

Relevance 6/10Novelty 2/10Timing: Filed after-hours on 2026-06-04; transaction dated 2026-06-02.

Background

The article is an SEC Form 4 insider transaction disclosure (officer/director selling issuer shares).

Company-level read

Ticker impact

$NOVTNeutralHigh confidence
Context

Novanta CEO Glastra Matthijs filed an open-market sale of 38 shares at $164.61 under a pre-arranged 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely limited and short-lived.

Evidence & confidence

Form 4 provides a disclosed transaction price/date but no new company-specific operational or financial information; 10b5-1 reduces interpretive weight.

Market effects

Sector

No clear sector read-through from a small, planned insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even planned 10b5-1 sales can coincide with internal expectations; however, the disclosed size here is small relative to holdings.

Key entities

  • issuer
    Novanta Inc

    Subject of the Form 4 insider transaction; CEO sold shares under a 10b5-1 plan.

  • insider
    Glastra Matthijs

    CEO and director who reported the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NOVT insider trading history →

Related articles

SEP 2
$AEISMed

Electronic Components Stocks Q2 Results: Benchmarking Advanced Energy (NASDAQ:AEIS)

Eight electronic components stocks reported Q2 revenues 3.3% above estimates, with next quarter's guidance 6.9% higher. Despite strong results, shares fell 7.2% on average. Advanced Energy (AEIS) saw $574.1M revenue (up 30% YoY, 5.6% beat), but its stock dropped 10%. Allient (ALNT) and Littelfuse (LFUS) also beat estimates, while nLIGHT (LASR) missed EBITDA guidance, falling 46.4%.

tradingview.com3 min
AUG 13
$NOVTMedAI 9/10

Novanta (NOVT) Q2 2026 Earnings Call Transcript

Novanta Inc. (NOVT) reported Q2 2026 revenue of $265.8 million, up 10.3% (9.3% organic). Adjusted EPS was $0.89, up 17.1%, with adjusted EBITDA of $60.7 million. The company raised 2026 guidance for revenue ($1.13B-$1.14B) and adjusted EBITDA ($273M-$278M) after completing the Riverpoint Medical acquisition, expected to add ~$65M revenue and ~$25M adjusted EBITDA in 2H26.

fool.com6 min
AUG 5
$NOVTHighAI 9/10

Novanta Announces Financial Results for the Second Quarter 2026

Novanta Inc. (Nasdaq: NOVT) reported Q2 2026 GAAP revenue of $265.8 million, up 10.3% year over year, and GAAP net income of $12.5 million. Adjusted EBITDA rose 16.4% to $60.7 million and adjusted diluted EPS increased 17.1% to $0.89. The company also closed the Riverpoint Medical acquisition and raised Q3 and FY 2026 guidance.

leaderpost.com6 min
AUG 5
$NOVTHigh

NOVANTA INC (NOVT): Results of Operations and Financial Condition

NOVANTA INC (NOVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE August 5, 2026 Novanta Announces Financial Results for the Second Quarter 2026 • Second Quarter 2026 GAAP Revenue increased 10% to $266 million • Second Quarter 2026 GAAP Net Income was $13 million, and Adjusted EBITDA increased 16% to $61 milli

SEC EDGAR 8-K6 min
JUL 27
$NOVTMedAI 8/10

Novanta Completes Acquisition of Riverpoint Medical

Novanta Inc. (Nasdaq: NOVT) said it has completed its acquisition of Riverpoint Medical from Arlington Capital Partners. Novanta expects the deal to double recurring medical consumables revenue to about $300 million, raise medical end-market exposure to 60%, deliver high single-digit ROIC by year three, and add $0.18 to $0.25 of adjusted EPS in 2027.

leaderpost.com5 min